)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ArcticZymes Technologies
ArcticZymes Technologies (AZT) investor relations material
ArcticZymes Technologies Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 sales revenue rose 15% YoY to NOK 32.9m, or 24% at constant currency, led by 44% Biomanufacturing growth.
9M sales rose 23% to NOK 96.6m; EBITDA increased to NOK 12.1m from NOK 3.7m, and EBIT turned profitable at NOK 5.3m.
Financial highlights
Q3 sales revenue was NOK 32.9m; total revenue was NOK 33.1m.
Q3 EBITDA was NOK 3.1m versus NOK 3.5m; EBIT was NOK 0.9m versus NOK 1.3m, and net profit was NOK 1.4m versus NOK 2.8m.
9M total revenue was NOK 102.1m; net profit rose to NOK 7.2m from NOK 3.0m.
At constant currency, estimated EBITDA was NOK 5.5m in Q3 and NOK 19.8m in 9M.
Outlook and guidance
2026–2028 ambition remains sustainable double-digit growth, market outperformance, EBITDA margin expansion, stronger cash generation, and selective value-accretive investment.
Priorities include scaling commercial execution, deeper workflow penetration, advancing R&D, expanding SAN GMP and NGS/metagenomics exposure, and establishing RNA as a growth pillar.
RNA revenue is expected to build as early-access customers adopt and scale the products; the portfolio is planned to expand over coming years.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ArcticZymes Technologies
- Recurring, high-margin enzyme sales drive scalable growth across diversified biotech markets.AZT
Pareto Securities' 17th Annual Healthcare Conference presentation - Q2 2026 delivered record revenue and EBITDA growth, driven by balanced segment performance.AZTQ2 2026
- Q1 2026 delivered 41% revenue growth, positive EBITDA, and strategic advances in RNA and biomanufacturing.AZTQ1 2026
- Scaling a diversified enzyme platform for double-digit growth in diagnostics and therapeutics.AZTCMD 2026
- Q4 2025 delivered 39% sales growth and a 232% EBITDA increase, with strong segment performance.AZTQ4 2025
- Innovative enzyme portfolio and strategic partnerships drive growth in advanced therapies.AZTSEB Arcticzymes Presentation Healthcare Seminar Presentation
- Biomanufacturing growth and strategic transformation position for future market leadership.AZTQ3 2024
- Record Q2 orders and new product launches signal future growth despite lower earnings.AZTQ2 2024
- EBITDA and margins rose as new GMP launches and customer growth set up 2025 recovery.AZTQ4 2024
Next ArcticZymes Technologies earnings date
Q4 202612 Feb, 2027
ArcticZymes Technologies
Next ArcticZymes Technologies earnings date
Q4 202612 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics, and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas. It provides enzymes for real-time PCR; enzymes for various applications; Norzym Taq DNA Polymerase for routine PCR applications; Menthazym Taq DNA Polymerase that enables amplification of DNA in low-copy templates; Toyzym Taq DNA Polymerase that enhances PCR sensitivity and specificity; MgGapFill DNTP Mix that produces more reliable qPCR results by maximizing efficiency and reducing nonspecific amplifications; and ZymoTaq Hotstart qPCR Mix that provides speed and convenience with the increased specificity of hot-start chemistry.